XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows (Used In) Operating Activities    
Net loss $ (1,549,253) $ (3,239,044)
Non-cash items:    
Stock-based compensation expense 585,701 180,791
Acquired in-process research and development 2,000,000
Depreciation expense 75 25
Expenses paid by Sanovas on behalf of Company, net 523,053 772,581
Changes in operating assets and liabilities:    
Increase in accounts payable and accrued liabilities 275,908 115,405
Increase in accrued interest payable 2,880 4,180
Total adjustments 1,387,617 3,072,982
Net cash (used in) operating activities (161,636) (166,062)
Cash Flows (used in) Investing activities - Equipment purchase (307)
Cash Flows From Financing Activities    
Proceeds from common stock sold, net of costs 60,500
Proceeds from exercise of options and warrants 25,000
Advances from related parties 161,642 79,534
Net cash provided by financing activities 161,642 165,034
Net increase (decrease) in cash 6 (1,315)
Cash at beginning of period 38 4,947
Cash at end of period 44 3,632
Supplemental information:    
Interest paid
Income taxes paid
Retirement of due to Sanovas through the issuance of common stock to Sanovas Ophthalmology LLC (Note C) 950,086 353,432
Offset of note payable-affiliates through the exercise of warrants $ 25,000